$PVCT, Provectus Biopharmaceuticals Announces
Post# of 22757
Posted On: 12/22/2016 8:33:48 AM
$PVCT,
Provectus Biopharmaceuticals Announces Two Poster Presentations on PV-10 for Liver Tumors
Clinical Interventional Oncology (CIO) on February 4-5, 2017
Asian Pacific Association for the Study of the Liver (APASL) on February 15-19, 2007
Thursday December 22, 2016
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB
VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"
, today announced acceptance of two abstracts for poster presentations at international oncology conferences in February 2017. Both abstracts describe data from the Company's phase 1 study of PV-10 in tumors of the liver (https://www.clinicaltrials.gov/ct2/show/NCT00986661).
The first abstract, titled "Percutaneous Rose Bengal as an Ablative Immunotherapy for Hepatic Metastases," to be presented at Clinical Interventional Oncology (CIO) on February 4-5, 2017, in Hollywood, Florida, focuses on outcome in patients with colorectal cancer that has metastasized to the liver.
The second abstract, titled "Intralesional Rose Bengal as an Ablative Immunotherapy for Hepatic Tumors," to be presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) on February 15-19, 2007, in Shanghai, China, focuses on outcome in patients with hepatocellular carcinoma.
Eric Wachter, Ph.D., Chief Technology Officer of Provectus, observed, "We are pleased to be able to update the oncology community on our investigation of PV-10 in tumors of the liver. Our phase 1 'basket study' allows us to collect data on a range of tumor types affecting the liver. CIO is an attractive venue to focus on results with tumors metastatic to the liver, which remains an important clinical challenge in the west. Similarly, the high incidence of hepatocellular carcinoma (primary liver cancer) in Asia makes Shanghai a tremendous opportunity to provide an update on HCC."
Provectus believes the posters will be available online following each conference.
The complete press release is available at http://www.provectusbio.com/news/press-releas...20161222-1 on the Provectus website.
Provectus Biopharmaceuticals Announces Two Poster Presentations on PV-10 for Liver Tumors
Clinical Interventional Oncology (CIO) on February 4-5, 2017
Asian Pacific Association for the Study of the Liver (APASL) on February 15-19, 2007
Thursday December 22, 2016
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB
VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company" , today announced acceptance of two abstracts for poster presentations at international oncology conferences in February 2017. Both abstracts describe data from the Company's phase 1 study of PV-10 in tumors of the liver (https://www.clinicaltrials.gov/ct2/show/NCT00986661). The first abstract, titled "Percutaneous Rose Bengal as an Ablative Immunotherapy for Hepatic Metastases," to be presented at Clinical Interventional Oncology (CIO) on February 4-5, 2017, in Hollywood, Florida, focuses on outcome in patients with colorectal cancer that has metastasized to the liver.
The second abstract, titled "Intralesional Rose Bengal as an Ablative Immunotherapy for Hepatic Tumors," to be presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) on February 15-19, 2007, in Shanghai, China, focuses on outcome in patients with hepatocellular carcinoma.
Eric Wachter, Ph.D., Chief Technology Officer of Provectus, observed, "We are pleased to be able to update the oncology community on our investigation of PV-10 in tumors of the liver. Our phase 1 'basket study' allows us to collect data on a range of tumor types affecting the liver. CIO is an attractive venue to focus on results with tumors metastatic to the liver, which remains an important clinical challenge in the west. Similarly, the high incidence of hepatocellular carcinoma (primary liver cancer) in Asia makes Shanghai a tremendous opportunity to provide an update on HCC."
Provectus believes the posters will be available online following each conference.
The complete press release is available at http://www.provectusbio.com/news/press-releas...20161222-1 on the Provectus website.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼